Pharmacokinetic and pharmacodynamic sub-study of trans-arterial vs. intravenous gemcitabine in the TIGeR-PaC phase 3 clinical trial.

Novelli PM, Zervos EE, Zureikat AH, Pishvaian MJ, Meredith K, Hatoum H, Nazemzadeh R, Laroia S, Kasi P, Bingham J, Agah R.

Open source

DOI: 10.1007/s00280-026-04939-0
Published: 2026-08-17
Container: Cancer Chemother Pharmacol
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00280-026-04939-0,
  title = {Pharmacokinetic and pharmacodynamic sub-study of trans-arterial vs. intravenous gemcitabine in the TIGeR-PaC phase 3 clinical trial.},
  author = {Novelli PM and  Zervos EE and  Zureikat AH and  Pishvaian MJ and  Meredith K and  Hatoum H and  Nazemzadeh R and  Laroia S and  Kasi P and  Bingham J and  Agah R.},
  year = {2026},
  journal = {Cancer Chemother Pharmacol},
  doi = {10.1007/s00280-026-04939-0},
  url = {https://doi.org/10.1007/s00280-026-04939-0}
}

RIS

TY  - JOUR
TI  - Pharmacokinetic and pharmacodynamic sub-study of trans-arterial vs. intravenous gemcitabine in the TIGeR-PaC phase 3 clinical trial.
AU  - Novelli PM
AU  -  Zervos EE
AU  -  Zureikat AH
AU  -  Pishvaian MJ
AU  -  Meredith K
AU  -  Hatoum H
AU  -  Nazemzadeh R
AU  -  Laroia S
AU  -  Kasi P
AU  -  Bingham J
AU  -  Agah R.
PY  - 2026
JO  - Cancer Chemother Pharmacol
DO  - 10.1007/s00280-026-04939-0
UR  - https://doi.org/10.1007/s00280-026-04939-0
ER  -

APA

PM, N., EE, Z., AH, Z., MJ, P., K, M., H, H., R, N., S, L., P, K., J, B., & R., A. (2026). Pharmacokinetic and pharmacodynamic sub-study of trans-arterial vs. intravenous gemcitabine in the TIGeR-PaC phase 3 clinical trial.. Cancer Chemother Pharmacol. https://doi.org/10.1007/s00280-026-04939-0

Source records

europe-pmc · retrieved 2026-09-25T10:38:34.152Z